This post was originally published on this site To advance the pipeline for innovative therapeutics in Alzheimer’s (AD), the National Institute on Aging (NIA) will invest an expected $73 million over five years in two new translational research centers. The centers will be funded through the NIA’s Alzheimer Centers for the Discovery of New Medicines program,…
This post was originally published on this site October is Breast Cancer Awareness Month, but what does that have to do with Alzheimer’s disease and caregiving? Nothing, except that women make up the majority of caregivers in the United States. This means that over 60 percent of caregivers are susceptible to breast cancer. Breast cancer…
This post was originally published on this site The National Institute on Aging (NIA) has awarded a five-year grant expected to total $53.4 million to Brown University and Hebrew SeniorLife to lead the creation and management of a research incubator to test Alzheimer’s and dementia care interventions in real-world settings. Called the NIA Imbedded Pragmatic AD/ADRD Clinical…
This post was originally published on this site Therapeutics that target brain immune cells known as microglia may prevent the formation of amyloid-beta plaques, one of the hallmarks of Alzheimer’s disease, according to a recent mouse study. The study, ”Sustained microglial depletion with CSF1R inhibitor impairs parenchymal plaque development in an Alzheimer’s disease model,” was…
This post was originally published on this site An upcoming and free web-based documentary series explores why efforts to develop an Alzheimer’s therapy are so challenging and often end in failure, and how individuals can lower their disease risk. The multi-part series “Alzheimer’s — The Science of Prevention,” opens globally on Oct. 9 and runs through Oct.…
This post was originally published on this site It’s easy to pass judgment on others about what they may be doing wrong. Unfortunately, because of this, caregivers are often the targets of unfair scrutiny. Alzheimer’s caregivers are frequently the subjects of pointing fingers, and folks looking on from the cheap seats are quite opinionated. Here’s…
This post was originally published on this site The first two patients with Alzheimer’s disease have been dosed with Cassava Sciences’ investigational small molecule PTI-125 in a new Phase 2b clinical study. PTI-125 is a small molecule that has been designed to bind to an abnormal form of a protein called Filamin A (or FLNA),…
This post was originally published on this site NeuroEM Therapeutics‘s MemorEMTM — a head-worn device that uses electromagnetic waves — has shown promising results in a preliminary clinical trial of people with mild-to-moderate Alzheimer’s disease. Seven of eight participants demonstrated improved memory after two months of treatment. The results, “A Clinical Trial of Transcranial Electromagnetic…
This post was originally published on this site Two global Phase 3 clinical trials — MISSION AD1 (NCT02956486) and MISSION AD2 (NCT03036280) — evaluating elenbecestat as a potential therapy for early Alzheimer’s disease are being stopped early, Eisai and Biogen announced. This decision was based on a safety review conducted by an independent data monitoring committee that found an unfavorable…
This post was originally published on this site For millions of Americans, elder abuse is an unfortunate consequence of aging. The National Council on Aging (NCOA) estimates that one in 10 seniors ages 60 and older have been abused in the U.S. Physical abuse is just one form of mistreatment that some elderly people endure…
